Antiretroviral therapy back on track with HIV-1 protease inhibitors.
References
Aboulker, J.P. & Swart, A.M. Preliminary analysis of the Concorde trial. Lancet 329, 889–890 (1993).
Fischl, M.A. et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122, 24–32 (1995).
Delfraissy, J.F. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p.69 (1993).
Danner, S.A. et al. Abstracts of the IXth Int. Conference on AIDS, Berlin, Germany, p.69 (1993).
Chow, Y.K. et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650–654 (1993).
Emini, E.A. et al. HIV and multidrug resistance. Nature 364, 679 (1993).
Larder, B.A., Kellam, P. & Kemp, S.D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365, 451–453 (1993).
Mellors, J.W. Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 175 (1996).
Hammer, S.M., Katzenstein, D.A., Hughes, M.D., Hirsch, M.S. & Merigan, T.C. Abstracts 3rd Conf. Retroviruses and Opportunistic Infections, Washington, DC, 175 (1996).
Cameron, B. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
Freimuth, W.W. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
Gulick, R. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.162 (1996).
Mathez, D. et al. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p. 106 (1996).
Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483–489 (1995).
Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117–122 (1995).
Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123–126 (1995).
Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.174 (1996).
Mellors, J. et al. Abstracts 35th Intersci. Conf. on Antimicrobial Agents and Chemotherapy, San Francisco, California, 235 (1995).
Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571 (1995).
Steigbigel, R.T. et al Abstracts 3rd Conf. Retrovir. & Opportun. Infect., Washington, DC, p.80 (1996).
Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333, 1528–1533 (1995).
Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333, 1534–1539 (1995).
Schapiro, J.M., Winters, M.A., Kozal, M.J. & Merigan, T.C. Abstracts 35th Intersci. Conf. Antimicrobial Agents and Chemotherapy, San Francisco, California, p.S8 (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mellors, J. Closing in on human immunodeficiency virus–1. Nat Med 2, 274–275 (1996). https://doi.org/10.1038/nm0396-274
Issue Date:
DOI: https://doi.org/10.1038/nm0396-274
- Springer Nature America, Inc.
This article is cited by
-
The ART of preventing HIV
Nature Medicine (2011)
-
Specificity of retroviral proteinases based on substrates containing tyrosine and proline at the site of cleavage
Pathology & Oncology Research (1997)